dabrafenib,trametinib,pembrolizumab
Novartis,merck
['melanoma']
remodeling clinical practice through clinical studies. neoadjuvant treatments seem to become a favorite modality in melanoma and can teach us quite a lot on tumor biology. neotrio trial by arts in chicago. #asco22 #artinstituteofchicago 
MD PhD, Dermatologist & Medical Oncologist, Chair, Melanoma and Skin Cancer center, Tel Aviv Medical Center